Loading…
Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial)
An open controlled trial of the use of galantamine at a maximum dose of 16 mg/day included 41 patients with Parkinson's disease with dementia randomized to a galantamine treatment group (21 patients) and a control group (20 patients). Cognitive, neuropsychiatric, and motor symptoms were assesse...
Saved in:
| Published in: | Neuroscience and behavioral physiology 2008-11, Vol.38 (9), p.937-945 |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3153-8d3f3b200978d2d150e75682c335e8a3a6b0b7327925123d3c0287c1e6b933ef3 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c3153-8d3f3b200978d2d150e75682c335e8a3a6b0b7327925123d3c0287c1e6b933ef3 |
| container_end_page | 945 |
| container_issue | 9 |
| container_start_page | 937 |
| container_title | Neuroscience and behavioral physiology |
| container_volume | 38 |
| creator | Litvinenko, I. V. Odinak, M. M. Mogil’naya, V. I. Emelin, A. Yu |
| description | An open controlled trial of the use of galantamine at a maximum dose of 16 mg/day included 41 patients with Parkinson's disease with dementia randomized to a galantamine treatment group (21 patients) and a control group (20 patients). Cognitive, neuropsychiatric, and motor symptoms were assessed clinically before the trial and at 4, 12, and 24 weeks, using the Mini Mental State Examination (MMSE), the cognitive Alzheimer's Disease Assessment Scale (ADAS-cog), the clock drawing test, the Frontal Assessment Battery (FAB), and the Neuropsychiatric Inventory (NPI) with assessment of distress in relatives. Patients treated with galantamine had better scores on the MMSE (
p
< 0.05),ADAS-cog (
p
< 0.05), the clock drawing test (
p
< 0.05), and the FAB (
p
< 0.01) at the end of the study period as compared with the control group. Changes in total point scores on the NPI-12 at the ends of weeks 12 and 24, as compared with the beginning of the trial, were in favor of the group treated with galantamine, with significant changes in the hallucinations (
p
= 0.0002), anxiety (
p
= 0.04), sleep disturbance (
p
= 0.04), and apathy (
p
= 0.006) sections. Galantamine treatment was accompanied by decreases in the level of distress in patients' relatives (
p
= 0.007) and improvements in daily activity (
p
= 0.003). Improvements in gait and decreases in freezing and falls were seen in the galantamine treatment group. However, two patients of this group showed minor increases in tremor. Side effects (drooling, postural hypotension, nausea, dysuria) occurred in seven patients (30%). |
| doi_str_mv | 10.1007/s11055-008-9077-3 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_19503715</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19503715</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3153-8d3f3b200978d2d150e75682c335e8a3a6b0b7327925123d3c0287c1e6b933ef3</originalsourceid><addsrcrecordid>eNp1kc2KFDEUhYMoTk_rA7iR4MJxFqU3yaRSWcow_sCALhTchVRyM2asStqkGqm3N003DAhmcwk559wcPkJeMHjLANS7yhhI2QEMnQalOvGIbJhUohu0_vGYbAC06kBe6TNyXus9NI8a4Ck5Y4NWkoHYkPUmhOisW6lNnlYbcFlpDvTOTjYtdo4J6ZuCba7TJQ25UI8zpiVaGhPd2SW2S6V_4vKTfrXlV0w1p4tKfaxoa_PaRPMOE3U5LSVPE3q6lGiny2fkSbBTxeenuSXfP9x8u_7U3X75-Pn6_W3nBJOtihdBjPxQZfDcMwmoZD9wJ4TEwQrbjzAqwZXmknHhhQM-KMewH7UQGMSWvD7m7kr-vce6mDlWh1Prh3lfDdMShGqrtuTVP8L7vC-p_c3wdnrZy6smYkeRK7nWgsHsSpxtWQ0Dc4BijlBMg2IOUIxonpen4P04o39wnCg0AT8KantKd1geNv8_9S-QC5Z5</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222265654</pqid></control><display><type>article</type><title>Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial)</title><source>Springer Link</source><creator>Litvinenko, I. V. ; Odinak, M. M. ; Mogil’naya, V. I. ; Emelin, A. Yu</creator><creatorcontrib>Litvinenko, I. V. ; Odinak, M. M. ; Mogil’naya, V. I. ; Emelin, A. Yu</creatorcontrib><description>An open controlled trial of the use of galantamine at a maximum dose of 16 mg/day included 41 patients with Parkinson's disease with dementia randomized to a galantamine treatment group (21 patients) and a control group (20 patients). Cognitive, neuropsychiatric, and motor symptoms were assessed clinically before the trial and at 4, 12, and 24 weeks, using the Mini Mental State Examination (MMSE), the cognitive Alzheimer's Disease Assessment Scale (ADAS-cog), the clock drawing test, the Frontal Assessment Battery (FAB), and the Neuropsychiatric Inventory (NPI) with assessment of distress in relatives. Patients treated with galantamine had better scores on the MMSE (
p
< 0.05),ADAS-cog (
p
< 0.05), the clock drawing test (
p
< 0.05), and the FAB (
p
< 0.01) at the end of the study period as compared with the control group. Changes in total point scores on the NPI-12 at the ends of weeks 12 and 24, as compared with the beginning of the trial, were in favor of the group treated with galantamine, with significant changes in the hallucinations (
p
= 0.0002), anxiety (
p
= 0.04), sleep disturbance (
p
= 0.04), and apathy (
p
= 0.006) sections. Galantamine treatment was accompanied by decreases in the level of distress in patients' relatives (
p
= 0.007) and improvements in daily activity (
p
= 0.003). Improvements in gait and decreases in freezing and falls were seen in the galantamine treatment group. However, two patients of this group showed minor increases in tremor. Side effects (drooling, postural hypotension, nausea, dysuria) occurred in seven patients (30%).</description><identifier>ISSN: 0097-0549</identifier><identifier>EISSN: 1573-899X</identifier><identifier>DOI: 10.1007/s11055-008-9077-3</identifier><identifier>PMID: 18975103</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Activities of Daily Living ; Aged ; Aged, 80 and over ; Behavioral Sciences ; Biomedical and Life Sciences ; Biomedicine ; Caregivers - psychology ; Cholinesterase Inhibitors - adverse effects ; Cholinesterase Inhibitors - therapeutic use ; Cognition - drug effects ; Dementia ; Dementia - complications ; Dementia - drug therapy ; Family ; Galantamine - adverse effects ; Galantamine - therapeutic use ; Humans ; Mental Status Schedule ; Middle Aged ; Motor Activity - drug effects ; Neurobiology ; Neurosciences ; Parkinson Disease - complications ; Parkinson Disease - drug therapy ; Severity of Illness Index ; Time Factors</subject><ispartof>Neuroscience and behavioral physiology, 2008-11, Vol.38 (9), p.937-945</ispartof><rights>Springer Science+Business Media, Inc. 2008</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3153-8d3f3b200978d2d150e75682c335e8a3a6b0b7327925123d3c0287c1e6b933ef3</citedby><cites>FETCH-LOGICAL-c3153-8d3f3b200978d2d150e75682c335e8a3a6b0b7327925123d3c0287c1e6b933ef3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18975103$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Litvinenko, I. V.</creatorcontrib><creatorcontrib>Odinak, M. M.</creatorcontrib><creatorcontrib>Mogil’naya, V. I.</creatorcontrib><creatorcontrib>Emelin, A. Yu</creatorcontrib><title>Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial)</title><title>Neuroscience and behavioral physiology</title><addtitle>Neurosci Behav Physi</addtitle><addtitle>Neurosci Behav Physiol</addtitle><description>An open controlled trial of the use of galantamine at a maximum dose of 16 mg/day included 41 patients with Parkinson's disease with dementia randomized to a galantamine treatment group (21 patients) and a control group (20 patients). Cognitive, neuropsychiatric, and motor symptoms were assessed clinically before the trial and at 4, 12, and 24 weeks, using the Mini Mental State Examination (MMSE), the cognitive Alzheimer's Disease Assessment Scale (ADAS-cog), the clock drawing test, the Frontal Assessment Battery (FAB), and the Neuropsychiatric Inventory (NPI) with assessment of distress in relatives. Patients treated with galantamine had better scores on the MMSE (
p
< 0.05),ADAS-cog (
p
< 0.05), the clock drawing test (
p
< 0.05), and the FAB (
p
< 0.01) at the end of the study period as compared with the control group. Changes in total point scores on the NPI-12 at the ends of weeks 12 and 24, as compared with the beginning of the trial, were in favor of the group treated with galantamine, with significant changes in the hallucinations (
p
= 0.0002), anxiety (
p
= 0.04), sleep disturbance (
p
= 0.04), and apathy (
p
= 0.006) sections. Galantamine treatment was accompanied by decreases in the level of distress in patients' relatives (
p
= 0.007) and improvements in daily activity (
p
= 0.003). Improvements in gait and decreases in freezing and falls were seen in the galantamine treatment group. However, two patients of this group showed minor increases in tremor. Side effects (drooling, postural hypotension, nausea, dysuria) occurred in seven patients (30%).</description><subject>Activities of Daily Living</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Behavioral Sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Caregivers - psychology</subject><subject>Cholinesterase Inhibitors - adverse effects</subject><subject>Cholinesterase Inhibitors - therapeutic use</subject><subject>Cognition - drug effects</subject><subject>Dementia</subject><subject>Dementia - complications</subject><subject>Dementia - drug therapy</subject><subject>Family</subject><subject>Galantamine - adverse effects</subject><subject>Galantamine - therapeutic use</subject><subject>Humans</subject><subject>Mental Status Schedule</subject><subject>Middle Aged</subject><subject>Motor Activity - drug effects</subject><subject>Neurobiology</subject><subject>Neurosciences</subject><subject>Parkinson Disease - complications</subject><subject>Parkinson Disease - drug therapy</subject><subject>Severity of Illness Index</subject><subject>Time Factors</subject><issn>0097-0549</issn><issn>1573-899X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><recordid>eNp1kc2KFDEUhYMoTk_rA7iR4MJxFqU3yaRSWcow_sCALhTchVRyM2asStqkGqm3N003DAhmcwk559wcPkJeMHjLANS7yhhI2QEMnQalOvGIbJhUohu0_vGYbAC06kBe6TNyXus9NI8a4Ck5Y4NWkoHYkPUmhOisW6lNnlYbcFlpDvTOTjYtdo4J6ZuCba7TJQ25UI8zpiVaGhPd2SW2S6V_4vKTfrXlV0w1p4tKfaxoa_PaRPMOE3U5LSVPE3q6lGiny2fkSbBTxeenuSXfP9x8u_7U3X75-Pn6_W3nBJOtihdBjPxQZfDcMwmoZD9wJ4TEwQrbjzAqwZXmknHhhQM-KMewH7UQGMSWvD7m7kr-vce6mDlWh1Prh3lfDdMShGqrtuTVP8L7vC-p_c3wdnrZy6smYkeRK7nWgsHsSpxtWQ0Dc4BijlBMg2IOUIxonpen4P04o39wnCg0AT8KantKd1geNv8_9S-QC5Z5</recordid><startdate>200811</startdate><enddate>200811</enddate><creator>Litvinenko, I. V.</creator><creator>Odinak, M. M.</creator><creator>Mogil’naya, V. I.</creator><creator>Emelin, A. Yu</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QR</scope><scope>7TK</scope><scope>7TS</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>200811</creationdate><title>Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial)</title><author>Litvinenko, I. V. ; Odinak, M. M. ; Mogil’naya, V. I. ; Emelin, A. Yu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3153-8d3f3b200978d2d150e75682c335e8a3a6b0b7327925123d3c0287c1e6b933ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Activities of Daily Living</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Behavioral Sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Caregivers - psychology</topic><topic>Cholinesterase Inhibitors - adverse effects</topic><topic>Cholinesterase Inhibitors - therapeutic use</topic><topic>Cognition - drug effects</topic><topic>Dementia</topic><topic>Dementia - complications</topic><topic>Dementia - drug therapy</topic><topic>Family</topic><topic>Galantamine - adverse effects</topic><topic>Galantamine - therapeutic use</topic><topic>Humans</topic><topic>Mental Status Schedule</topic><topic>Middle Aged</topic><topic>Motor Activity - drug effects</topic><topic>Neurobiology</topic><topic>Neurosciences</topic><topic>Parkinson Disease - complications</topic><topic>Parkinson Disease - drug therapy</topic><topic>Severity of Illness Index</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Litvinenko, I. V.</creatorcontrib><creatorcontrib>Odinak, M. M.</creatorcontrib><creatorcontrib>Mogil’naya, V. I.</creatorcontrib><creatorcontrib>Emelin, A. Yu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Physical Education Index</collection><collection>ProQuest - Health & Medical Complete保健、医学与药学数据库</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database (ProQuest)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>Neuroscience and behavioral physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Litvinenko, I. V.</au><au>Odinak, M. M.</au><au>Mogil’naya, V. I.</au><au>Emelin, A. Yu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial)</atitle><jtitle>Neuroscience and behavioral physiology</jtitle><stitle>Neurosci Behav Physi</stitle><addtitle>Neurosci Behav Physiol</addtitle><date>2008-11</date><risdate>2008</risdate><volume>38</volume><issue>9</issue><spage>937</spage><epage>945</epage><pages>937-945</pages><issn>0097-0549</issn><eissn>1573-899X</eissn><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-1</notes><notes>content type line 23</notes><abstract>An open controlled trial of the use of galantamine at a maximum dose of 16 mg/day included 41 patients with Parkinson's disease with dementia randomized to a galantamine treatment group (21 patients) and a control group (20 patients). Cognitive, neuropsychiatric, and motor symptoms were assessed clinically before the trial and at 4, 12, and 24 weeks, using the Mini Mental State Examination (MMSE), the cognitive Alzheimer's Disease Assessment Scale (ADAS-cog), the clock drawing test, the Frontal Assessment Battery (FAB), and the Neuropsychiatric Inventory (NPI) with assessment of distress in relatives. Patients treated with galantamine had better scores on the MMSE (
p
< 0.05),ADAS-cog (
p
< 0.05), the clock drawing test (
p
< 0.05), and the FAB (
p
< 0.01) at the end of the study period as compared with the control group. Changes in total point scores on the NPI-12 at the ends of weeks 12 and 24, as compared with the beginning of the trial, were in favor of the group treated with galantamine, with significant changes in the hallucinations (
p
= 0.0002), anxiety (
p
= 0.04), sleep disturbance (
p
= 0.04), and apathy (
p
= 0.006) sections. Galantamine treatment was accompanied by decreases in the level of distress in patients' relatives (
p
= 0.007) and improvements in daily activity (
p
= 0.003). Improvements in gait and decreases in freezing and falls were seen in the galantamine treatment group. However, two patients of this group showed minor increases in tremor. Side effects (drooling, postural hypotension, nausea, dysuria) occurred in seven patients (30%).</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>18975103</pmid><doi>10.1007/s11055-008-9077-3</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0097-0549 |
| ispartof | Neuroscience and behavioral physiology, 2008-11, Vol.38 (9), p.937-945 |
| issn | 0097-0549 1573-899X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_19503715 |
| source | Springer Link |
| subjects | Activities of Daily Living Aged Aged, 80 and over Behavioral Sciences Biomedical and Life Sciences Biomedicine Caregivers - psychology Cholinesterase Inhibitors - adverse effects Cholinesterase Inhibitors - therapeutic use Cognition - drug effects Dementia Dementia - complications Dementia - drug therapy Family Galantamine - adverse effects Galantamine - therapeutic use Humans Mental Status Schedule Middle Aged Motor Activity - drug effects Neurobiology Neurosciences Parkinson Disease - complications Parkinson Disease - drug therapy Severity of Illness Index Time Factors |
| title | Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial) |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T01%3A40%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20galantamine%20(reminyl)%20for%20dementia%20in%20patients%20with%20Parkinson's%20disease%20(an%20open%20controlled%20trial)&rft.jtitle=Neuroscience%20and%20behavioral%20physiology&rft.au=Litvinenko,%20I.%20V.&rft.date=2008-11&rft.volume=38&rft.issue=9&rft.spage=937&rft.epage=945&rft.pages=937-945&rft.issn=0097-0549&rft.eissn=1573-899X&rft_id=info:doi/10.1007/s11055-008-9077-3&rft_dat=%3Cproquest_cross%3E19503715%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3153-8d3f3b200978d2d150e75682c335e8a3a6b0b7327925123d3c0287c1e6b933ef3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=222265654&rft_id=info:pmid/18975103&rfr_iscdi=true |